Compare SLI & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLI | ARVN |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 524.3M | 600.2M |
| IPO Year | 2011 | 2018 |
| Metric | SLI | ARVN |
|---|---|---|
| Price | $1.86 | $7.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | $5.25 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 1.6M | 747.1K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.82 | $6.97 |
| 52 Week High | $6.40 | $14.22 |
| Indicator | SLI | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 30.01 | 30.22 |
| Support Level | N/A | N/A |
| Resistance Level | $2.67 | $9.69 |
| Average True Range (ATR) | 0.12 | 0.33 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 5.38 | 5.85 |
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.